source
- Setara Biosciences raises $90 million Series A to advance Jazz-spun rare disease programsSetara Biosciences has been created to focus on a set of rare-disease assets that Jazz Pharmaceuticals retained after acquiring Actio Biosciences. The new company secured $90 million in Series A f…
- Congress must restore independence of scientific advisory panels after controversial firingsThe authors note the recent dismissal of two vice chairs of the U.S. Preventive Services Task Force by HHS Secretary Robert F. Kennedy Jr., stressing the panel’s role in reviewing evidence to guide…